trending Market Intelligence /marketintelligence/en/news-insights/trending/iH43jG4_nds5Cwv9SeNk7Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

NeuroVive raises 28.2M Swedish kronor in direct issue of shares

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

NeuroVive raises 28.2M Swedish kronor in direct issue of shares

NeuroVive Pharmaceutical AB raised 28.2 million Swedish kronor in gross proceeds from a directed new issuance of 20,897,854 shares.

Each share in the issue was priced at 1.35 Swedish kronor, a 5.1% discount to the closing price of NeuroVive's share listed on the Nasdaq Stockholm on March 6.

Proceeds from the issuance will be used to advance drug development activities.

Stockholm Corporate Finance was the financial adviser and sole book runner for the issue.

As of March 13, US$1 was equivalent to 9.31 Swedish kronor.